{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-059527","form_type":"8-K","ticker":"ANTX","cik":"0001880438","company_name":"AN2 Therapeutics, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.072497+00:00","generated_at":"2026-06-02T01:20:05.008813+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AN2 Therapeutics Q1 net loss $16.6M; Phase 2 TR-MAC data expected August 2024","bullets":["Net loss of $16.6M for Q1 2024 vs $15.3M in Q1 2023; cash $118.1M.","R&D spend $14.7M, up from $12.0M YoY; G&A $3.6M, down from $4.1M.","Phase 3 enrollment paused Feb 2024 due to blinded aggregate efficacy signal; no safety issues.","97 patients remain in Phase 3; topline Phase 2 data from EBO-301 due August 2024.","Epetraborole targets treatment-refractory MAC lung disease with high unmet need."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-059527","json":"https://secwatch.observer/filing/0000950170-24-059527.json","markdown":"https://secwatch.observer/filing/0000950170-24-059527.md","text":"https://secwatch.observer/filing/0000950170-24-059527.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024059527/0000950170-24-059527-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024059527/antx-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:20:05.008813+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"242bd1b7d1fa53bc75a9c8dd06333647b1be5c3f","claim":"AN2 Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 was $16.6 million.","evidence_excerpt":"AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024059527/0000950170-24-059527-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss for the first quarter of 2024 was $16.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}